Results 41 to 50 of about 766 (168)
Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm. [PDF]
Int J Mol Sci: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the overexpression of CD123 and CD303 surface antigens.
Galati D +5 more
europepmc +3 more sources
Journal of Investigative Medicine High Impact Case Reports, 2022 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive malignancy with poor outcomes. Although novel options like tagraxofusp, a CD123-directed cytotoxin, has emerged and is promising, treatment options are very limited in the relapsed
Prashanth Ashok Kumar MBBS +5 more
doaj +1 more source
Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease-directed progress. [PDF]
Br J HaematolSummary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Ngo TQ +3 more
europepmc +2 more sources
CD123-targeting immunotherapeutic approaches in acute myeloid leukaemia. [PDF]
Br J HaematolSummary Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with ...
Dreyzin A, Holtzman NG, Bonifant CL.
europepmc +2 more sources
Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia
Human Vaccines & Immunotherapeutics, 2020 The IL-3 alpha chain receptor (CD123) is a cell surface protein that is widely expressed by various subtypes of acute leukemia, including acute myeloid leukemia (AML), acute lymphoblastic leukemia and blastic plasmacytoid dendritic cell neoplasm. Notably,
Ibrahim Aldoss +3 more
doaj +1 more source
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm [PDF]
Blood Advances, 2020 AbstractBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically challenging hematologic malignancy with dismal outcomes. With a median age of ∼70 years, the majority of patients with BPDCN have experienced historically suboptimal responses with intensive chemotherapy regimens.
Naveen Pemmaraju, Marina Konopleva
openaire +2 more sources
CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm
, 2022 SIMPLE SUMMARY: Until recently, there were no approved therapies for the aggressive blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN). Survival for patients diagnosed with BPDCN is under two years, and improved treatments are needed.
Naveen Pemmaraju +9 more
core +1 more source
Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm
Cancer Management and Research, 2022 Yumeng Zhang,1,2 Lubomir Sokol2 1Department of Internal Medicine, University of South Florida, Tampa, FL, USA; 2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USACorrespondence: Yumeng Zhang; Lubomir Sokol, Email yumeng.zhang ...
Zhang Y, Sokol L
doaj
Hematology, Transfusion and Cell Therapy, 2023 Introdução/Objetivos: A NCDPB é uma doença rara, com comportamento agressivo e prognóstico sombrio, perfazendo menos de 0,5% de todas as neoplasias hematológicas. O trabalho visa expor o relato de caso sobre a mesma, com os desafios e limitações impostas
JPS Siqueira +9 more
doaj +1 more source
, 2020 International audienceBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy, for which conventional chemotherapy has poor outcomes.
Beziat, Guillaume, Ysebaert, Loïc
core +1 more source